Innovation-driven trend shaping COVID-19 vaccine development in China.
10.1007/s11684-023-1034-6
- Author:
Yuntao ZHANG
1
;
Yuxiu ZHAO
1
;
Hongyang LIANG
1
;
Ying XU
1
;
Chuge ZHOU
1
;
Yuzhu YAO
1
;
Hui WANG
2
;
Xiaoming YANG
3
Author Information
1. China National Biotec Group Company Limited, Beijing, 100029, China.
2. China National Biotec Group Company Limited, Beijing, 100029, China. wanghui5@sinopharm.com.
3. China National Biotec Group Company Limited, Beijing, 100029, China. yangxiaoming@sinopharm.com.
- Publication Type:Review
- Keywords:
COVID-19 vaccine;
SARS-CoV-2;
vaccine development
- MeSH:
Humans;
COVID-19 Vaccines;
COVID-19/prevention & control*;
SARS-CoV-2;
China/epidemiology*;
Vaccine Development
- From:
Frontiers of Medicine
2023;17(6):1096-1116
- CountryChina
- Language:English
-
Abstract:
Confronted with the Coronavirus disease 2019 (COVID-19) pandemic, China has become an asset in tackling the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission and mutation, with several innovative platforms, which provides various technical means in this persisting combat. Derived from collaborated researches, vaccines based on the spike protein of SARS-CoV-2 or inactivated whole virus are a cornerstone of the public health response to COVID-19. Herein, we outline representative vaccines in multiple routes, while the merits and plights of the existing vaccine strategies are also summarized. Likewise, new technologies may provide more potent or broader immunity and will contribute to fight against hypermutated SARS-CoV-2 variants. All in all, with the ultimate aim of delivering robust and durable protection that is resilient to emerging infectious disease, alongside the traditional routes, the discovery of innovative approach to developing effective vaccines based on virus properties remains our top priority.
